EnteroMedics Announces First Commercial Shipment of the Maestro(R) Rechargeable System to Australia

EnteroMedics Inc.

today announced that it has made the first commercial shipment of the Maestro® Rechargeable System to its distribution partner in Australia, Device Technologies Pty Ltd. The Maestro RC System delivers VBLOC® vagal blocking therapy, a first-in-class weight loss treatment designed to control both hunger and fullness by blocking the primary nerve which regulates the digestive system. The Maestro RC System has received CE Mark for the treatment of obesity and has been listed on the Australian Register of Therapeutic Goods for commercial sale in Australia. "This first commercial shipment of our Maestro RC System marks a major milestone for EnteroMedics, supporting our evolution to a commercial enterprise and bringing us closer to our goal of delivering safer, effective and sustainable weight-loss treatments to patients worldwide," said Mark B. Knudson, Ph.D., EnteroMedics' President and Chief Executive Officer. "Australians will be among the first people in the world with the option to choose VBLOC therapy to treat their obesity. VBLOC allows patients to take a positive path towards weight loss, addressing the lifelong challenge of obesity and its comorbidities, such as diabetes, without sacrificing wellbeing or comfort."